These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9265968)

  • 41. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
    Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
    Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Look before you leap. Carrier screening for type 1 Gaucher disease: difficult questions.
    Borry P; Clarke A; Dierickx K
    Eur J Hum Genet; 2008 Feb; 16(2):139-40. PubMed ID: 18043719
    [No Abstract]   [Full Text] [Related]  

  • 43. Molecular analysis of Turkish Gaucher disease patients: identification of novel mutations in glucocerebrosidase (GBA) gene.
    Emre S; Gürakan F; Yüce A; Rolf A; Scott R; Ozen H
    Eur J Med Genet; 2008; 51(4):315-21. PubMed ID: 18586596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular studies on parents after autopsy identify recombinant GBA gene in a case of Gaucher disease with ichthyosis phenotype.
    Aggarwal S; Jain SJ; Bhowmik AD; Tandon A; Dalal A
    Am J Med Genet A; 2015 Nov; 167A(11):2858-60. PubMed ID: 26172087
    [No Abstract]   [Full Text] [Related]  

  • 45. Molecular biology of glucocerebrosidase and the treatment of Gaucher disease.
    Barranger JA; Tomich J; Weiler S; Sakallah S; Sansieri C; Mifflin T; Bahnson A; Wei FS; Wei JF; Vallor M
    Cytokines Mol Ther; 1995 Sep; 1(3):149-63. PubMed ID: 9384672
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gaucher disease-associated glucocerebrosidases show mutation-dependent chemical chaperoning profiles.
    Sawkar AR; Adamski-Werner SL; Cheng WC; Wong CH; Beutler E; Zimmer KP; Kelly JW
    Chem Biol; 2005 Nov; 12(11):1235-44. PubMed ID: 16298303
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.
    Marshall J; McEachern KA; Kyros JA; Nietupski JB; Budzinski T; Ziegler RJ; Yew NS; Sullivan J; Scaria A; van Rooijen N; Barranger JA; Cheng SH
    Mol Ther; 2002 Aug; 6(2):179-89. PubMed ID: 12161184
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and secretion of human glucocerebrosidase mediated by recombinant lentivirus vectors in vitro and in vivo: implications for gene therapy of Gaucher disease.
    Kim EY; Hong YB; Lai Z; Kim HJ; Cho YH; Brady RO; Jung SC
    Biochem Biophys Res Commun; 2004 May; 318(2):381-90. PubMed ID: 15120612
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gaucher disease in the dog.
    Farrow BR; Hartley WJ; Pollard AC; Fabbro D; Grabowski GA; Desnick RJ
    Prog Clin Biol Res; 1982; 95():645-53. PubMed ID: 6812090
    [No Abstract]   [Full Text] [Related]  

  • 50. Chemical chaperones and permissive temperatures alter localization of Gaucher disease associated glucocerebrosidase variants.
    Sawkar AR; Schmitz M; Zimmer KP; Reczek D; Edmunds T; Balch WE; Kelly JW
    ACS Chem Biol; 2006 May; 1(4):235-51. PubMed ID: 17163678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
    Chang HH; Asano N; Ishii S; Ichikawa Y; Fan JQ
    FEBS J; 2006 Sep; 273(17):4082-92. PubMed ID: 16934036
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Platelet function and coagulation abnormalities in type 1 Gaucher disease patients: effects of enzyme replacement therapy (ERT).
    Giona F; Palumbo G; Amendola A; Santoro C; Mazzuconi MG
    J Thromb Haemost; 2006 Aug; 4(8):1831-3. PubMed ID: 16879228
    [No Abstract]   [Full Text] [Related]  

  • 53. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system.
    Shaaltiel Y; Bartfeld D; Hashmueli S; Baum G; Brill-Almon E; Galili G; Dym O; Boldin-Adamsky SA; Silman I; Sussman JL; Futerman AH; Aviezer D
    Plant Biotechnol J; 2007 Sep; 5(5):579-90. PubMed ID: 17524049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gaucher disease in South Africa.
    Heitner R
    S Afr Med J; 2008 Jan; 98(1):11-2. PubMed ID: 18270627
    [No Abstract]   [Full Text] [Related]  

  • 55. [Organization of Gaucher disease management in France].
    Stirnemann J; de Villemeur TB; Belmatoug N
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S198-201. PubMed ID: 18228688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gaucher type 2 disease: identification of a novel transversion mutation in a French-Irish patient.
    Choy FY; Humphries ML; Ben-Yoseph Y
    Am J Med Genet; 1998 Jun; 78(1):92-3. PubMed ID: 9637431
    [No Abstract]   [Full Text] [Related]  

  • 57. Inhibitors and stimulators of glucocerebroside metabolism.
    Radin NS
    Prog Clin Biol Res; 1982; 95():357-83. PubMed ID: 6214799
    [No Abstract]   [Full Text] [Related]  

  • 58. Identification of a novel three-nucleotide insertion mutation (c.841-842insTGA) in the acid beta-glucosidase gene of a Taiwan Chinese patient with type II Gaucher disease.
    Wu JY; Wu MC; Lee CC; Tsai FJ
    Hum Mutat; 2001 Mar; 17(3):238. PubMed ID: 11241851
    [No Abstract]   [Full Text] [Related]  

  • 59. A new gene-pseudogene fusion allele due to a recombination in intron 2 of the glucocerebrosidase gene causes Gaucher disease.
    Cormand B; Díaz A; Grinberg D; Chabás A; Vilageliu L
    Blood Cells Mol Dis; 2000 Oct; 26(5):409-16. PubMed ID: 11112377
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Recent clinical progress in Gaucher disease.
    Grabowski GA
    Curr Opin Pediatr; 2005 Aug; 17(4):519-24. PubMed ID: 16012266
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.